One of Europe’s highest courts on Wednesday gave its blessing to a new merger control approach adopted by the European Commission in March of last year with the aim of curbing killer acquisitions, particularly in the pharma and tech industries.

Under this new approach, the European Commission’s antitrust watchdog can scrutinize merger deals on possible competition concerns even when those deals do not meet any of the revenue thresholds that trigger scrutiny by competition authorities at the national level.